|
RS53118B
(sr)
*
|
2003-02-26 |
2014-06-30 |
Sugen Inc. |
Aminoheteroaril jedinjenja kao inhibitori protein kinaze
|
|
BRPI0507834A
(pt)
*
|
2004-02-23 |
2007-07-10 |
Sugen Inc |
método para tratar o crescimento celular anormal usando inibidores de c-met e de m-tor
|
|
EP1719762B1
(en)
*
|
2004-02-27 |
2012-06-27 |
Eisai R&D Management Co., Ltd. |
Novel pyridine derivative and pyrimidine derivative (1)
|
|
CN1989131A
(zh)
*
|
2004-03-30 |
2007-06-27 |
希龙公司 |
取代的噻吩衍生物用作抗癌药
|
|
CN1960969B
(zh)
*
|
2004-04-01 |
2012-03-28 |
伊莱利利公司 |
组胺h3受体药物、其制备方法及治疗用途
|
|
US8008301B2
(en)
|
2004-04-01 |
2011-08-30 |
Eli Lilly And Company |
Histamine H3 receptor agents, preparation and therapeutic uses
|
|
US7705025B2
(en)
|
2004-08-23 |
2010-04-27 |
Eli Lilly And Company |
Histamine H3 receptor agents, preparation and therapeutic uses
|
|
ATE492544T1
(de)
*
|
2004-08-26 |
2011-01-15 |
Pfizer |
Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
|
|
WO2006021886A1
(en)
*
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
|
|
GEP20104906B
(en)
*
|
2004-08-26 |
2010-02-25 |
Pfizer |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
|
KR20070038571A
(ko)
*
|
2004-08-26 |
2007-04-10 |
화이자 인코포레이티드 |
단백질 티로신 키나제 저해제 중간체의 제조를 위한거울상이성질선택적 생물학적 전환
|
|
GT200600042A
(es)
*
|
2005-02-10 |
2006-09-27 |
Aventis Pharma Inc |
Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
|
|
JP2008535790A
(ja)
*
|
2005-03-03 |
2008-09-04 |
サートリス ファーマシューティカルズ， インコーポレイテッド |
サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体
|
|
JP2008540575A
(ja)
*
|
2005-05-13 |
2008-11-20 |
レキシコン・ファーマシューティカルズ・インコーポレーテッド |
多環系化合物とその使用の方法
|
|
US8088928B2
(en)
*
|
2005-08-04 |
2012-01-03 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
EP1909910A1
(en)
*
|
2005-08-04 |
2008-04-16 |
Sirtris Pharmaceuticals, Inc. |
Benzimidazole derivatives as sirtuin modulators
|
|
US8093401B2
(en)
*
|
2005-08-04 |
2012-01-10 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
US7855289B2
(en)
*
|
2005-08-04 |
2010-12-21 |
Sirtris Pharmaceuticals, Inc. |
Sirtuin modulating compounds
|
|
PL1889836T3
(pl)
*
|
2005-08-24 |
2013-10-31 |
Eisai R&D Man Co Ltd |
Nowa pochodna pirydyny i pochodna pirymidyny (3)
|
|
KR101146852B1
(ko)
*
|
2005-12-05 |
2012-05-16 |
화이자 프로덕츠 인크. |
Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체
|
|
BRPI0619424B1
(pt)
*
|
2005-12-05 |
2022-02-08 |
Pfizer Products Inc |
Uso de inibidores c-met/hgfrs para a fabricação de medicamentos
|
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
|
MX2008011220A
(es)
|
2006-03-07 |
2008-09-11 |
Array Biopharma Inc |
Compuestos de pirazol heterobiciclicos y metodos de uso.
|
|
WO2007111904A2
(en)
*
|
2006-03-22 |
2007-10-04 |
Vertex Pharmaceuticals Incorporated |
C-met protein kinase inhibitors for the treatment of proliferative disorders
|
|
US8168383B2
(en)
|
2006-04-14 |
2012-05-01 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
|
EP2447359B1
(en)
|
2006-04-14 |
2015-11-04 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
|
US7601716B2
(en)
|
2006-05-01 |
2009-10-13 |
Cephalon, Inc. |
Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
|
|
EP2338488A1
(en)
*
|
2006-05-26 |
2011-06-29 |
Bayer HealthCare, LLC |
Drug combinations with substituted diaryl ureas for the treatment of cancer
|
|
US20110053931A1
(en)
*
|
2006-06-08 |
2011-03-03 |
John Gaudino |
Quinoline compounds and methods of use
|
|
JP2010500365A
(ja)
|
2006-08-07 |
2010-01-07 |
インサイト・コーポレイション |
キナーゼ阻害剤としてのトリアゾロトリアジン
|
|
CN101454311B
(zh)
|
2006-08-23 |
2013-03-27 |
卫材R&D管理有限公司 |
苯氧基吡啶衍生物的盐和其结晶及其制备方法
|
|
US7790885B2
(en)
*
|
2006-08-31 |
2010-09-07 |
Eisai R&D Management Co., Ltd. |
Process for preparing phenoxypyridine derivatives
|
|
WO2008042867A2
(en)
*
|
2006-09-29 |
2008-04-10 |
Emiliem Inc. |
Modulators of multiple kinases
|
|
ES2555803T3
(es)
|
2006-10-23 |
2016-01-08 |
Cephalon, Inc. |
Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
|
|
GB0621607D0
(en)
*
|
2006-10-31 |
2006-12-06 |
Chroma Therapeutics Ltd |
Inhibitors of c-Met
|
|
ES2560435T3
(es)
|
2006-11-22 |
2016-02-19 |
Incyte Holdings Corporation |
Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
|
|
MY148851A
(en)
|
2006-12-14 |
2013-06-14 |
Bayer Ip Gmbh |
Dihydropyridine derivatives as useful as protein kinase inhibitors
|
|
JP2010516680A
(ja)
*
|
2007-01-19 |
2010-05-20 |
エックスカバリー，インコーポレイテッド |
キナーゼ阻害薬化合物
|
|
JPWO2008087736A1
(ja)
*
|
2007-01-19 |
2010-05-06 |
宇部興産株式会社 |
アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
|
|
ES2529790T3
(es)
|
2007-04-13 |
2015-02-25 |
Dana-Farber Cancer Institute, Inc. |
Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
|
|
US7981888B2
(en)
*
|
2007-04-16 |
2011-07-19 |
Abbott Laboratories |
1-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivatives
|
|
US8263585B2
(en)
|
2007-05-04 |
2012-09-11 |
Novartis Ag |
Organic compounds
|
|
CL2008001822A1
(es)
*
|
2007-06-20 |
2009-03-13 |
Sirtris Pharmaceuticals Inc |
Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
|
|
US20100190777A1
(en)
*
|
2007-07-17 |
2010-07-29 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
AU2008278966B2
(en)
*
|
2007-07-26 |
2012-02-23 |
Novartis Ag |
Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
|
|
CN101855342B
(zh)
|
2007-09-13 |
2013-07-10 |
科德克希思公司 |
用于还原苯乙酮的酮还原酶多肽
|
|
AU2008317107B2
(en)
*
|
2007-10-23 |
2013-09-12 |
Allergan, Inc. |
Therapeutic substituted lactams
|
|
CA2704336A1
(en)
*
|
2007-11-01 |
2009-05-07 |
Sirtris Pharmaceuticals, Inc. |
Amide derivatives as sirtuin modulators
|
|
JP2011503066A
(ja)
*
|
2007-11-08 |
2011-01-27 |
サートリス ファーマシューティカルズ， インコーポレイテッド |
可溶化チアゾロピリジン誘導体
|
|
JP2009132660A
(ja)
*
|
2007-11-30 |
2009-06-18 |
Eisai R & D Management Co Ltd |
食道癌治療用組成物
|
|
WO2009073224A1
(en)
*
|
2007-12-07 |
2009-06-11 |
Ambit Biosciences Corp. |
Methods of treating certain diseases using pyrimidine derivatives
|
|
US20090227556A1
(en)
*
|
2008-01-31 |
2009-09-10 |
Eisai R&D Management Co., Ltd. |
Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
|
|
WO2009096198A1
(ja)
*
|
2008-02-01 |
2009-08-06 |
Pharma Ip Limited Liability Intermediary Corporations |
新規ビアリール誘導体
|
|
EP2265270A1
(en)
*
|
2008-02-04 |
2010-12-29 |
OSI Pharmaceuticals, Inc. |
2-aminopyridine kinase inhibitors
|
|
AR070317A1
(es)
|
2008-02-06 |
2010-03-31 |
Osi Pharm Inc |
Furo (3,2-c) piridina y tieno (3,2-c) piridinas
|
|
JPWO2009104520A1
(ja)
*
|
2008-02-18 |
2011-06-23 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
フェノキシピリジン誘導体の製造方法（２）
|
|
US20110092452A1
(en)
*
|
2008-03-05 |
2011-04-21 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
|
US8268834B2
(en)
*
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
FR2928924B1
(fr)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
|
|
FR2928922B1
(fr)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
|
|
FR2928923B1
(fr)
|
2008-03-21 |
2010-04-23 |
Sanofi Aventis |
Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
|
|
US20110039860A1
(en)
*
|
2008-05-07 |
2011-02-17 |
Cangming Yang |
Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
|
|
MX393622B
(es)
|
2008-05-21 |
2025-03-24 |
Incyte Corp |
Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
|
|
CA2728408C
(en)
*
|
2008-06-19 |
2017-12-05 |
Congxin Liang |
Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
|
|
CA2734172A1
(en)
*
|
2008-08-29 |
2010-03-04 |
Genentech, Inc. |
Diagnostics and treatments for vegf-independent tumors
|
|
WO2010046780A2
(en)
*
|
2008-10-22 |
2010-04-29 |
Institut Pasteur Korea |
Anti viral compounds
|
|
AT507187B1
(de)
|
2008-10-23 |
2010-03-15 |
Helmut Dr Buchberger |
Inhalator
|
|
WO2010059771A1
(en)
|
2008-11-20 |
2010-05-27 |
Osi Pharmaceuticals, Inc. |
Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
|
|
EP2375904B1
(en)
*
|
2008-12-09 |
2014-05-28 |
Merck Sharp & Dohme Corp. |
Biaryl carboxamides
|
|
BRPI0924084B1
(pt)
|
2008-12-19 |
2021-12-21 |
Vertex Pharmaceuticals Incorporated |
Derivados de pirazina e composição farmacêutica que os compreende
|
|
EA021424B1
(ru)
|
2008-12-19 |
2015-06-30 |
Сертрис Фармасьютикалз, Инк. |
Тиазолопиридиновые соединения, регулирующие сиртуин
|
|
JP2012102018A
(ja)
*
|
2009-03-03 |
2012-05-31 |
Astellas Pharma Inc |
アミド化合物
|
|
TW201100441A
(en)
*
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
|
DE102009056886A1
(de)
|
2009-12-03 |
2011-06-09 |
Bayer Schering Pharma Aktiengesellschaft |
cMet-Inhibitoren zur Behandlung der Endometriose
|
|
JP5714030B2
(ja)
|
2010-02-03 |
2015-05-07 |
インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
|
|
US8916593B2
(en)
|
2010-05-04 |
2014-12-23 |
Pfizer Inc. |
Alkoxy-substituted 2-aminopyridines as ALK inhibitors
|
|
US9062008B2
(en)
*
|
2010-05-12 |
2015-06-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
EP2569287B1
(en)
|
2010-05-12 |
2014-07-09 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
AU2011253025A1
(en)
|
2010-05-12 |
2012-11-29 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
WO2011143646A1
(en)
|
2010-05-14 |
2011-11-17 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
US10010439B2
(en)
|
2010-06-13 |
2018-07-03 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
|
US8628554B2
(en)
|
2010-06-13 |
2014-01-14 |
Virender K. Sharma |
Intragastric device for treating obesity
|
|
US10420665B2
(en)
|
2010-06-13 |
2019-09-24 |
W. L. Gore & Associates, Inc. |
Intragastric device for treating obesity
|
|
US9526648B2
(en)
|
2010-06-13 |
2016-12-27 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
|
CA2802644C
(en)
|
2010-06-25 |
2017-02-21 |
Eisai R & D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
|
JP2013531687A
(ja)
|
2010-07-16 |
2013-08-08 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ナトリウムチャネル遮断剤としてのピリジン化合物
|
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
|
US9126947B2
(en)
|
2010-10-08 |
2015-09-08 |
Xcovery Holding Company Llc |
Substituted pyridazine carboxamide compounds
|
|
JP6000273B2
(ja)
|
2010-11-29 |
2016-09-28 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
大環状キナーゼ阻害剤
|
|
GB201021103D0
(en)
*
|
2010-12-13 |
2011-01-26 |
Univ Leuven Kath |
New compounds for the treatment of neurodegenerative diseases
|
|
JP5681819B2
(ja)
|
2011-02-11 |
2015-03-11 |
バットマーク・リミテッド |
吸入器コンポーネント
|
|
WO2012116050A2
(en)
*
|
2011-02-24 |
2012-08-30 |
Eternity Bioscience Inc. |
Phosphorus containing compounds as protein kinase inhibitors
|
|
US9145390B2
(en)
|
2011-03-03 |
2015-09-29 |
Concert Pharmaceuticals, Inc. |
Derivatives of pyrazole-substituted amino-heteroaryl compounds
|
|
JO3363B1
(ar)
*
|
2011-04-13 |
2019-03-13 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
|
BR112013028895A2
(pt)
|
2011-05-10 |
2016-08-09 |
Bayer Ip Gmbh |
(tio)carbonilamidinas bicíclicas
|
|
EP2710003A1
(en)
|
2011-05-16 |
2014-03-26 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
JP2014517079A
(ja)
|
2011-06-22 |
2014-07-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
WO2013013308A1
(en)
*
|
2011-07-27 |
2013-01-31 |
Beta Pharma Canada Inc. |
Spirocyclic molecules as protein kinase inhibitors
|
|
HK1198133A1
(en)
|
2011-08-02 |
2015-03-13 |
辉瑞公司 |
Crizotinib for use in the treatment of cancer
|
|
SG10201606774UA
(en)
|
2011-09-30 |
2016-10-28 |
Vertex Pharma |
Processes for making compounds useful as inhibitors of atr kinase
|
|
IN2014CN02501A
(enExample)
|
2011-09-30 |
2015-06-26 |
Vertex Pharma |
|
|
WO2013132376A1
(en)
|
2012-03-06 |
2013-09-12 |
Pfizer Inc. |
Macrocyclic derivatives for the treatment of proliferative diseases
|
|
AU2013203824A1
(en)
|
2012-03-16 |
2013-10-03 |
Purdue Pharma L.P. |
Substituted pyridines and pryimidines as sodium channel blockers
|
|
US20140044802A1
(en)
|
2012-04-05 |
2014-02-13 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
and combination therapies thereof
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
KR102117982B1
(ko)
|
2012-04-13 |
2020-06-03 |
에피자임, 인코포레이티드 |
암 치료용 병용 요법
|
|
CN103387535B
(zh)
*
|
2012-05-10 |
2016-06-01 |
广东东阳光药业有限公司 |
取代的炔基吡啶化合物及其使用方法和用途
|
|
WO2013177092A1
(en)
*
|
2012-05-23 |
2013-11-28 |
Sunshine Lake Pharma Co., Ltd. |
Substituted alkynyl pyridine compounds and methods of use
|
|
SG10201610869TA
(en)
|
2012-06-26 |
2017-02-27 |
Del Mar Pharmaceuticals |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
|
|
GB201211310D0
(en)
*
|
2012-06-26 |
2012-08-08 |
Chroma Therapeutics Ltd |
CSF-1R kinase inhibitors
|
|
DK2898329T3
(en)
|
2012-09-24 |
2017-07-17 |
Ventana Med Syst Inc |
PROCEDURE FOR IDENTIFYING TREATMENT RESPONSIBLE NON-SMALL CELL LUNG CANCER USING ANAPLASTIC Lymphoma Kinase (ALK) AS MARKER
|
|
DK2904406T3
(en)
|
2012-10-04 |
2018-06-18 |
Vertex Pharma |
METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
|
|
WO2014081816A1
(en)
*
|
2012-11-21 |
2014-05-30 |
Concert Pharmaceuticals, Inc. |
Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds
|
|
SMT202000713T1
(it)
|
2012-12-07 |
2021-03-15 |
Vertex Pharma |
Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
|
|
WO2014096941A1
(en)
|
2012-12-20 |
2014-06-26 |
Purdue Pharma L.P. |
Cyclic sulfonamides as sodium channel blockers
|
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
|
RU2671212C2
(ru)
*
|
2013-02-02 |
2018-10-30 |
Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд |
Замещенный 2-аминопиридин в качестве ингибитора протеинкиназы
|
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
|
EP2983674A4
(en)
|
2013-04-08 |
2017-05-10 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
|
CN105264380B
(zh)
|
2013-05-14 |
2017-09-05 |
卫材R&D管理有限公司 |
用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
|
|
WO2015034729A1
(en)
*
|
2013-09-05 |
2015-03-12 |
Calitor Sciences, Llc |
Substituted pyridine compounds and methods of use
|
|
US20160214961A1
(en)
*
|
2013-09-10 |
2016-07-28 |
Shilpa Medicare Limited |
Novel salts of crizotinib and their preparation
|
|
RU2550346C2
(ru)
|
2013-09-26 |
2015-05-10 |
Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" |
Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
|
|
AU2013402175B2
(en)
|
2013-09-30 |
2017-09-07 |
Handok Inc. |
Novel triazolopyrazine derivative and use thereof
|
|
EP3066118B1
(en)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
HUE046727T2
(hu)
|
2013-12-06 |
2020-03-30 |
Vertex Pharma |
Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
|
|
KR20160100329A
(ko)
|
2013-12-20 |
2016-08-23 |
3-브이 바이오사이언시스, 인코포레이티드 |
지질 합성의 헤테로사이클릭 조절물질 및 이들의 조합물
|
|
CN103755627B
(zh)
*
|
2014-01-09 |
2016-02-17 |
定陶县友帮化工有限公司 |
2-氨基-3-羟基-5-氯吡啶的合成方法
|
|
TWI672141B
(zh)
|
2014-02-20 |
2019-09-21 |
美商醫科泰生技 |
投予ｒｏｓ１突變癌細胞之分子
|
|
MX2016012285A
(es)
|
2014-03-24 |
2017-01-23 |
Genentech Inc |
Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
|
|
US10730866B2
(en)
|
2014-04-07 |
2020-08-04 |
Purdue Pharma L.P. |
Indole derivatives and use thereof
|
|
WO2015167825A1
(en)
|
2014-04-29 |
2015-11-05 |
Emory University |
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
|
|
WO2015172747A1
(en)
*
|
2014-05-16 |
2015-11-19 |
Zhaoyin Wang |
Spirocyclic molecules as mth1 inhibitors
|
|
CN107074863B
(zh)
|
2014-06-05 |
2019-12-03 |
沃泰克斯药物股份有限公司 |
Atr激酶抑制剂的制备方法及其不同的固体形式
|
|
PL3157566T3
(pl)
|
2014-06-17 |
2019-10-31 |
Vertex Pharma |
Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
|
|
WO2016019909A1
(zh)
*
|
2014-08-07 |
2016-02-11 |
江苏豪森药业股份有限公司 |
一种抗癌化合物的新晶型及其制备方法和用途
|
|
WO2016028971A1
(en)
|
2014-08-21 |
2016-02-25 |
Bristol-Myers Squibb Company |
Tied-back benzamide derivatives as potent rock inhibitors
|
|
CA2957005C
(en)
|
2014-08-28 |
2021-10-12 |
Eisai R&D Management Co., Ltd. |
High-purity quinoline derivative and method for manufacturing same
|
|
WO2016061097A1
(en)
|
2014-10-13 |
2016-04-21 |
Atrin Pharmaceuticals LLC |
Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
|
|
GB2535427A
(en)
|
2014-11-07 |
2016-08-24 |
Nicoventures Holdings Ltd |
Solution
|
|
UY36391A
(es)
*
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
|
|
US10662183B2
(en)
|
2014-11-07 |
2020-05-26 |
The Regents Of The University Of Michigan |
Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same
|
|
KR102595599B1
(ko)
|
2014-12-02 |
2023-11-02 |
이그니타, 인코포레이티드 |
신경모세포종의 치료를 위한 병용
|
|
EP3246046A4
(en)
|
2015-01-13 |
2018-12-05 |
Kyoto University |
Agent for preventing and/or treating amyotrophic lateral sclerosis
|
|
MA41598A
(fr)
*
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
SG11201706630UA
(en)
|
2015-02-25 |
2017-09-28 |
Eisai R&D Man Co Ltd |
Method for suppressing bitterness of quinoline derivative
|
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
|
WO2016198691A1
(en)
|
2015-06-11 |
2016-12-15 |
Basilea Pharmaceutica Ag |
Efflux-pump inhibitors and therapeutic uses thereof
|
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
|
US10405627B2
(en)
*
|
2015-07-14 |
2019-09-10 |
Michael Charles Boland, III |
Luggage with fold out table
|
|
JP6553726B2
(ja)
|
2015-08-20 |
2019-07-31 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
|
KR102678021B1
(ko)
|
2015-09-30 |
2024-06-26 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
|
|
GB2542838B
(en)
|
2015-10-01 |
2022-01-12 |
Nicoventures Trading Ltd |
Aerosol provision system
|
|
CN108697661A
(zh)
|
2015-12-18 |
2018-10-23 |
亚尼塔公司 |
用于治疗癌症的组合
|
|
US11129808B2
(en)
|
2016-03-15 |
2021-09-28 |
University Of South Florida |
PKC-delta-I inhibitor formulations and uses thereof
|
|
US10301324B2
(en)
|
2016-04-12 |
2019-05-28 |
Atrin Pharmaceuticals LLC |
Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use
|
|
US10779980B2
(en)
|
2016-04-27 |
2020-09-22 |
Synerz Medical, Inc. |
Intragastric device for treating obesity
|
|
US10933068B2
(en)
*
|
2016-05-26 |
2021-03-02 |
Sonic Master Limited |
Modulators of DUX4 for regulation of muscle function
|
|
TWI646094B
(zh)
|
2016-06-01 |
2019-01-01 |
大陸商貝達藥業股份有限公司 |
Crystal form of inhibitory protein kinase active compound and application thereof
|
|
EP3558992A4
(en)
|
2016-12-15 |
2020-12-02 |
ONO Pharmaceutical Co., Ltd. |
TREK CHANNEL ACTIVATOR (K + CHANNELS ASSOCIATED WITH TWIK)
|
|
CN106866627B
(zh)
*
|
2017-01-24 |
2021-09-14 |
南方医科大学 |
3-(1-(氨基吡啶氧基)乙基)苯甲酰胺衍生物及其合成方法和应用
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
BR112019023064A2
(pt)
|
2017-05-16 |
2020-06-09 |
Eisai R&D Man Co Ltd |
tratamento de carcinoma hepatocelular
|
|
JP2020527588A
(ja)
|
2017-07-18 |
2020-09-10 |
ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． |
アデノシンアンタゴニストとしてのヘテロ環式化合物
|
|
BR112020000962A2
(pt)
|
2017-07-18 |
2020-07-14 |
Nuvation Bio Inc. |
compostos de 1,8-naftiridinona e usos dos mesmos
|
|
EP3654952A1
(en)
|
2017-07-19 |
2020-05-27 |
Ignyta, Inc. |
Pharmaceutical compositions comprising entrectinib
|
|
JP7311498B2
(ja)
|
2017-10-17 |
2023-07-19 |
イグナイタ インコーポレイテッド |
薬学的組成物および剤形
|
|
CN107794282B
(zh)
*
|
2017-11-20 |
2020-12-25 |
浙江工业大学 |
一种克唑替尼手性中间体的制备方法及菌株
|
|
WO2019154665A1
(en)
*
|
2018-02-07 |
2019-08-15 |
Basf Se |
New pyridine carboxamides
|
|
JP7034512B2
(ja)
*
|
2018-03-15 |
2022-03-14 |
フーチェン ハイシィ ファーマシューティカルズ シーオー．，エルティーディー |
キナーゼ阻害剤としてのヘテロアリール化合物
|
|
CN110372664A
(zh)
*
|
2018-04-13 |
2019-10-25 |
华东理工大学 |
选择性jak2抑制剂及其应用
|
|
WO2019206049A1
(en)
*
|
2018-04-25 |
2019-10-31 |
Zhuhai Yufan Biotechnologies Co., Ltd |
Hpk1 inhibitors, preparation method and application thereof
|
|
CN110396087A
(zh)
*
|
2018-04-25 |
2019-11-01 |
珠海宇繁生物科技有限责任公司 |
Hpk1激酶抑制剂、制备方法及其应用
|
|
CN108947895B
(zh)
*
|
2018-08-22 |
2021-09-24 |
肇庆中彩机电技术研发有限公司 |
一种抗癌活性的化合物
|
|
BR112021013936A2
(pt)
|
2019-01-18 |
2021-09-21 |
Nuvation Bio Inc. |
Compostos heterocíclicos como antagonistas de adenosina
|
|
CN113939291A
(zh)
|
2019-01-18 |
2022-01-14 |
诺维逊生物股份有限公司 |
1,8-萘啶酮化合物及其用途
|
|
EP3911325A4
(en)
*
|
2019-01-18 |
2022-10-12 |
Nuvation Bio Inc. |
HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
|
|
EP3941916B1
(en)
|
2019-03-20 |
2025-10-01 |
Emory University |
Prostaglandin receptor ep2 antagonists, derivatives, and uses related thereto
|
|
JP7345901B2
(ja)
|
2019-05-14 |
2023-09-19 |
テリジーン リミテッド |
キナーゼ阻害剤として有用な置換大員環類
|
|
EP4725489A2
(en)
|
2019-08-02 |
2026-04-15 |
OneHealthCompany, Inc. |
Treatment of canine cancers
|
|
KR102426921B1
(ko)
|
2019-09-24 |
2022-07-29 |
주식회사 이노보테라퓨틱스 |
헤테로아릴아미도피리딘올 유도체 및 이를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약학적 조성물
|
|
CN112552293A
(zh)
*
|
2019-09-25 |
2021-03-26 |
珠海宇繁生物科技有限责任公司 |
一种protac小分子化合物及其应用
|
|
KR102344185B1
(ko)
*
|
2020-02-26 |
2021-12-27 |
계명대학교 산학협력단 |
신규한 Pim 키나아제 억제제 및 이의 용도
|
|
CN113493437B
(zh)
*
|
2020-04-03 |
2022-07-26 |
中国药科大学 |
含苯并咪唑结构的化合物及其制备方法和用途
|
|
WO2021196655A1
(zh)
*
|
2020-04-03 |
2021-10-07 |
中国药科大学 |
含苯并咪唑结构的化合物及其制备方法与用途
|
|
WO2023086671A1
(en)
*
|
2021-11-15 |
2023-05-19 |
The Broad Institute, Inc. |
Compounds, compositions, and methods for inducing antimicrobial intracellular activity and for preventing and treating microbial infections
|
|
EP4552648A1
(en)
|
2022-07-04 |
2025-05-14 |
Chugai Seiyaku Kabushiki Kaisha |
Combination drug
|
|
WO2024048555A1
(ja)
|
2022-08-30 |
2024-03-07 |
中外製薬株式会社 |
併用医薬
|
|
WO2026071043A1
(en)
*
|
2024-09-30 |
2026-04-02 |
Alivexis, Inc. |
Kit inhibitors, compounds, pharmaceutical compositions, and methods of use thereof
|